Tivanisiran (SYL1001) is a siRNA used for the study of dry eye disease. Tivanisiran was designed to silence transient receptor potential vanilloid 1 (TRPV1).

In vitro transfection of tivanisiran was shown to produce a 50-60% decrease in TRPV1 mRNA levels[1][2].

1848224-71-4

Tivanisiran;SYL1001;Tivanisiran

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years